MAIA Biotechnology Inc.
MAIA Biotechnology, Inc., together with its subsidiaries, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positiv… Read more
MAIA Biotechnology Inc. (MAIA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -83.670x
Based on the latest financial reports, MAIA Biotechnology Inc. (MAIA) has a cash flow conversion efficiency ratio of -83.670x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.49 Million) by net assets ($41.67K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
MAIA Biotechnology Inc. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how MAIA Biotechnology Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
MAIA Biotechnology Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MAIA Biotechnology Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Citizens Bancshares Corp
PINK:CZBS
|
0.020x |
|
Carnaby Resources Ltd
AU:CNB
|
-0.074x |
|
PADAUK Technology Co. Ltd
TWO:6716
|
0.030x |
|
Shenzhen Zhongzhuang Construction Group Co Ltd
SHE:002822
|
-0.006x |
|
Bio-FD&C Co. Ltd.
KQ:251120
|
0.028x |
|
Ratnaveer Precision Engineering Ltd
NSE:RATNAVEER
|
N/A |
|
Leo Lithium Limited
PINK:LLLAF
|
-0.017x |
|
Plastron Precision Co Ltd
TWO:6185
|
0.049x |
Annual Cash Flow Conversion Efficiency for MAIA Biotechnology Inc. (2019–2024)
The table below shows the annual cash flow conversion efficiency of MAIA Biotechnology Inc. from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $3.63 Million | $-15.70 Million | -4.321x | +84.22% |
| 2023-12-31 | $477.51K | $-13.07 Million | -27.373x | -1825.30% |
| 2022-12-31 | $8.51 Million | $-12.10 Million | -1.422x | -216.61% |
| 2021-12-31 | $9.18 Million | $-4.12 Million | -0.449x | -139.36% |
| 2020-12-31 | $-1.62 Million | $-1.84 Million | 1.141x | +196.58% |
| 2019-12-31 | $1.32 Million | $-1.57 Million | -1.181x | -- |